Abivax presented its third-quarter 2025 financial results, reporting cash and cash equivalents of EUR 589.7 million as of September 30, 2025, providing a cash runway into Q4 2027. The company’s key financial information was reviewed by the Board of Directors and external auditors, with updates on business goals and operational achievements highlighted in press releases.

For the nine months ended September 30, 2025, Abivax reported an operating loss of EUR 174.4 million, an increase from EUR 130.2 million in the same period in 2024. Operating income decreased to EUR 4.1 million, with research and development expenses rising by EUR 25.4 million, driven by various clinical programs and supply chain costs.

Sales and marketing expenses decreased to EUR 3.4 million, while general and administrative costs increased to EUR 41.8 million for the nine months ending September 30, 2025. The company’s financial gain (loss) of EUR 79.7 million was influenced by factors like fair value adjustments, foreign exchange losses, and interest expenses.

Abivax ended the period with cash and cash equivalents of EUR 589.7 million, a significant increase from EUR 144.2 million at the end of 2024. The rise was mainly due to proceeds from a public offering in July 2025. Debt repayments were made, and various share conversions were completed during the period, enhancing the company’s financial position.

Based on existing cash reserves, Abivax anticipates funding its forecasted cash flow requirements into Q4 2027. The company’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for treating ulcerative colitis. Abivax continues to focus on developing therapies for chronic inflammatory diseases, leveraging natural regulatory mechanisms to stabilize the immune response in patients.

Read more at GlobeNewswire: Abivax Presents Third Quarter 2025 Financial Results